For instance, trastuzumab (a mAb against HER2) dramatically improved survival in HER2-positive breast cancer, and immune checkpoint antibodies (e.g., anti-PD-1/PD-L1) have produced durable remissions in multiple tumor types. This evidence concerns the gene ERBB2 and neoplasm.